Clinical Trial Update: Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity, safety and tolerability of the Chiron Meningococcal C Conjugate Vaccine in healthy premature and full-term 3-month-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Chiron Meningococcal C Conjugate Vaccine (Meningococcal C conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Prevention of Meningococcal Infection | Phase 3 | Status: COMPLETED